Conflicts of interest/Disclosures: Rebecca L. Robinson and Madelaine Wohlreich are employees of, and minor shareholders in, Eli Lilly and Company. Philip Mease receives research funding, consulting fees, and is an honoraria speaker for Eli Lilly and Company, Forest Pharmaceuticals, and Pfizer. David Williams is a consultant for Eli Lilly and Company, Forest Pharmaceuticals, Pfizer, Jazz Pharmaceuticals, and Bristol Myers Squibb. Yi Chen and Deborah D'Souza are employees of PharmaNet/i3. Bill McCarberg is an advisor for NeurogesX.
Burden of Illness and Treatment Patterns for Patients with Fibromyalgia
Version of Record online: 7 SEP 2012
Wiley Periodicals, Inc.
Volume 13, Issue 10, pages 1366–1376, October 2012
How to Cite
Robinson, R. L., Kroenke, K., Mease, P., Williams, D. A., Chen, Y., D'Souza, D., Wohlreich, M. and McCarberg, B. (2012), Burden of Illness and Treatment Patterns for Patients with Fibromyalgia. Pain Medicine, 13: 1366–1376. doi: 10.1111/j.1526-4637.2012.01475.x
- Issue online: 15 OCT 2012
- Version of Record online: 7 SEP 2012
Objective. This study was designed to describe burden of illness and treatment patterns, and to examine the patient, physician, and care factors associated with the treatment choices of individuals receiving new prescriptions for fibromyalgia (FM).
Design. This is a baseline assessment of the Real-World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (REFLECTIONS), a prospective observational study. Baseline data (including a physician survey, a patient visit form, and computer-assisted telephone interviews) were collected from July 2008 through May 2010 in 58 care settings in the United States, including Puerto Rico.
Results. Patients (N = 1,700) were mostly female (94.6%) and white (82.9%). Mean age was 50.4 years and mean duration of illness was 5.6 years. Mean Fibromyalgia Impact Questionnaire total score was 54.4 (range 0–80), and Brief Pain Inventory average pain severity level was 5.5 (range 0–10). Patients reported high annual health care use and numerous work limitations related to FM. Patients were taking 182 unique types of medications prescribed for FM, including duloxetine (26.8%), nonsteroidal anti-inflammatory drugs (26.6%), pregabalin (24.5%), opioids (24.2%), tramadol (15.3%), benzodiazepines (15.2%), cyclobenzaprine (12.9%), milnacipran (8.9%), and others. Most patients took more than one medication concurrently (77.8%). Type of current medications used was most strongly associated with medication history and physician specialty.
Conclusions. Burden of illness was high for patients with FM, and treatment patterns were highly variable. Importantly, the treatments with the most evidence to support their use were not always the most frequently chosen.